In recent years, anticoagulant medications—also known as blood thinners—other than warfarin, have come on the market in the United States. Blood thinners are often necessary to prevent dangerous blood clots and stroke. Newer generation blood thinners, such as Xarelto, Pradaxa, and Eliquis, are marketed as being easier for patients than warfarin because monthly blood tests are not required and certain dietary restrictions are not required. Yet these medications come with their own risk. Specifically, these newer generation blood thinners may result in excessive bleeding that cannot be stopped.
Xarelto (rivaroxaban) is an anti-coagulant drug made by Bayer, marketed by Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, and approved by the Food and Drug Administration (FDA) in 2011. The drug was approved to treat deep vein thrombosis and to prevent dangerous blood clots. Unfortunately, the medication has also been linked to excessive bleeding, including uncontrollable internal bleeding, bleeding in the brain, retinal bleeding, and bleeding in other parts of the body. As of August 2017, there is no FDA-approved antidote to reverse the effects of Xarelto related bleeds.
Lawsuits have been filed against Bayer and Janssen for the injuries suffered by patients taking Xarelto.
Pradaxa (dabigatran) was approved by the FDA in 2010 as a blood thinner for patients with atrial fibrillation who are at risk of suffering a stroke. Soon after the FDA approval, however, patients and their healthcare providers began reporting uncontrollable internal bleeding. Some of these bleeds were particularly dangerous and included brain hemorrhages, vascular bleeding, and gastrointestinal bleeding. The first reversal agent for uncontrollable bleeding was not approved by the FDA until 2015.
In May 2014, Boehringer Ingelheim, the maker of Pradaxa, agreed to settle more than 4,000 injury lawsuits for about $650 million. However, additional cases may be filed by people who have been hurt by this medication.
Eliquis (apixaban) is made by Bristol-Myers Squibb and marketed by Bristol-Myers Squibb and Pfizer. It was approved by the FDA in 2012. Like other blood thinners, it was approved to prevent blood clots in patients with atrial fibrillation not caused by a heart valve problem, and, like other blood thinners, it has been linked to excessive and uncontrollable bleeding.
The FDA approval process of this drug has been criticized and the FDA has had to change its own warnings for this drug several times since its initial approval. Individuals who have been hurt have also filed lawsuits alleging fraud, failure to warn about side effects, and false advertising against the pharmaceutical companies that make and market this drug.
As of August 2017, there is no FDA-approved antidote for excessive bleeding caused by Eliquis.
Contact an Alabama Drug Injury Lawyer for Help
Drug injury cases are complicated, and large pharmaceutical companies have the resources and incentive to fight back hard against any claims that are filed against them. If you have suffered an injury or your loved one has died because of uncontrollable bleeding from a blood thinner, then you need to speak with an experienced lawyer as soon as possible. Please contact us via this website or by phone today for a free, no-obligation consultation today.